tradingkey.logo

Illumina Inc

ILMN
View Detailed Chart
119.720USD
-13.890-10.40%
Close 02/06, 16:00ETQuotes delayed by 15 min
18.32BMarket Cap
21.83P/E TTM

Illumina Inc

119.720
-13.890-10.40%
Intraday
1m
30m
1h
D
W
M
D

Today

-10.40%

5 Days

-17.33%

1 Month

-18.62%

6 Months

+26.78%

Year to Date

-8.72%

1 Year

-2.51%

View Detailed Chart

TradingKey Stock Score of Illumina Inc

Currency: USD Updated: 2026-02-06

Key Insights

Illumina Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 43 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 136.64.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Illumina Inc's Score

Industry at a Glance

Industry Ranking
43 / 205
Overall Ranking
133 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Illumina Inc Highlights

StrengthsRisks
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 21.83, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.13M shares, decreasing 11.60% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.98K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.31.

Analyst Rating

Based on 20 analysts
Hold
Current Rating
136.636
Target Price
+2.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Illumina Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Illumina Inc Info

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Ticker SymbolILMN
CompanyIllumina Inc
CEOThaysen (Jacob)
Websitehttps://www.illumina.com
KeyAI